文献速递免疫规划传染病防控与疫情报告

奥密克戎流行期间成人(≥20岁)COVID-19住院疫苗有效性:I-MOVE-COVID-19与VEBIS SARI VE网络,欧洲,2021至2022年

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
PubMed 文献 · Euro Surveill · 2023-01-01

基于欧洲13国46家医院2021年12月至2022年7月奥密克戎流行期的检测阴性病例对照研究,纳入2779例病例和2362例对照。完成基础免疫且末剂接种≥150天者疫苗有效性为43%(95%CI:29-54),加种一剂加强针后升至59%(95%CI:51-66)。加强针接种后14-59天、60-119天和120-179天发病者疫苗有效性分别为85%(95%CI:78-89)、70%(95%CI:61-77)和36%(95%CI:17-51)。

要点

  • 完成基础免疫且末剂≥150天者疫苗有效性43%(95%CI:29-54)
  • 加种一剂加强针后疫苗有效性升至59%(95%CI:51-66)
  • 加强针后14-59天、60-119天、120-179天发病者疫苗有效性分别为85%、70%、36%

核心结论

  • 奥密克戎流行期间,观察到疫苗对SARI住院的有效性随首剂mRNA加强针接种而提高,尤其对首剂加强针后<120天发病者。

研究设计与样本

  • I-MOVE-COVID-19与VEBIS医院网络在13个国家46家医院采用相似的检测阴性病例对照方案。
  • 纳入2021年12月至2022年7月≥20岁因严重急性呼吸道感染(SARI)住院且PCR确诊SARS-CoV-2的患者。
  • 完全基础免疫(PSV)和首剂加强针定义为末剂接种距症状出现≥14天,首剂加强针按距末剂PSV<150天和≥150天分层。
  • 分析按固定效应调整站点,并调整拭子日期、年龄、性别及至少一种常见慢性病的有无。

主要发现

  • 共纳入2779例病例和2362例对照。
  • 所有疫苗产品合并后,完全PSV(末剂≥150天前接种)对实验室确诊SARS-CoV-2住院的疫苗有效性为43%(95%CI:29-54)。
  • 加种一剂加强针后疫苗有效性为59%(95%CI:51-66)。
  • 加强针接种后14-59天、60-119天和120-179天发病者疫苗有效性分别为85%(95%CI:78-89)、70%(95%CI:61-77)和36%(95%CI:17-51)。

关键数值与推荐

  • 完全PSV(末剂≥150天前接种)疫苗有效性43%(95%CI:29-54)。
  • 加种一剂加强针后疫苗有效性59%(95%CI:51-66)。
  • 加强针后14-59天发病者疫苗有效性85%(95%CI:78-89)。
  • 加强针后60-119天发病者疫苗有效性70%(95%CI:61-77)。
  • 加强针后120-179天发病者疫苗有效性36%(95%CI:17-51)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period).MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition.ResultsWe included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively.ConclusionsOur results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Rose AM, Nicolay N, Sandonis Martín V, et al. Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022. Euro Surveill. 2023. PMID: 37997665. doi:10.2807/1560-7917.ES.2023.28.47.2300187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。